Show simple item record

dc.contributor.authorMitchell, Helen
dc.date.accessioned2009-08-21T08:49:17Z
dc.date.available2009-08-21T08:49:17Z
dc.date.issued2004
dc.identifier.citationGoserelin ('Zoladex')-offering patients more choice in early breast cancer. 2004, 8 Suppl 2:S95-103 Eur J Oncol Nursen
dc.identifier.issn1462-3889
dc.identifier.pmid15590321
dc.identifier.doi10.1016/j.ejon.2004.09.004
dc.identifier.urihttp://hdl.handle.net/10541/78094
dc.description.abstractThe luteinising hormone-releasing hormone analogue goserelin ('Zoladex') suppresses ovarian oestrogen production in pre- and perimenopausal women. Goserelin is a biodegradable, sustained-release 3.6 mg depot that is administered by subcutaneous injection every 28 days. Clinical trials in premenopausal women with hormone-sensitive early breast cancer have demonstrated that goserelin alone, or in combination with tamoxifen, is at least as effective as cyclophosphamide, methotrexate, 5-fluorouracil (CMF) chemotherapy. Goserelin plus tamoxifen after cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) chemotherapy resulted in improved disease-free survival compared with CAF alone. These trials have also shown that goserelin is well tolerated and is associated with less acute toxicity than cytotoxic chemotherapy. Early improvements in quality of life over the first 3-6 months of goserelin treatment support the use of this agent as an alternative to chemotherapy in this patient population. Patients should be provided with information on the benefits and risks associated with available treatment options so that they can be involved in the decision-making process.
dc.language.isoenen
dc.subjectBreast Canceren
dc.subjectCancer Stagingen
dc.subject.meshAdult
dc.subject.meshAntineoplastic Agents, Hormonal
dc.subject.meshBreast Neoplasms
dc.subject.meshChemotherapy, Adjuvant
dc.subject.meshDelayed-Action Preparations
dc.subject.meshDrug Administration Schedule
dc.subject.meshFemale
dc.subject.meshGoserelin
dc.subject.meshGreat Britain
dc.subject.meshHumans
dc.subject.meshInjections, Subcutaneous
dc.subject.meshMastectomy
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasm Staging
dc.subject.meshPremenopause
dc.subject.meshPrognosis
dc.subject.meshRandomized Controlled Trials as Topic
dc.subject.meshRisk Assessment
dc.subject.meshSurvival Analysis
dc.subject.meshTreatment Outcome
dc.titleGoserelin ('Zoladex')-offering patients more choice in early breast cancer.en
dc.typeArticleen
dc.contributor.departmentChristie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. helen.mitchell@christie-tr.nwest.nhs.uken
dc.identifier.journalEuropean Journal of Oncology Nursingen
html.description.abstractThe luteinising hormone-releasing hormone analogue goserelin ('Zoladex') suppresses ovarian oestrogen production in pre- and perimenopausal women. Goserelin is a biodegradable, sustained-release 3.6 mg depot that is administered by subcutaneous injection every 28 days. Clinical trials in premenopausal women with hormone-sensitive early breast cancer have demonstrated that goserelin alone, or in combination with tamoxifen, is at least as effective as cyclophosphamide, methotrexate, 5-fluorouracil (CMF) chemotherapy. Goserelin plus tamoxifen after cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) chemotherapy resulted in improved disease-free survival compared with CAF alone. These trials have also shown that goserelin is well tolerated and is associated with less acute toxicity than cytotoxic chemotherapy. Early improvements in quality of life over the first 3-6 months of goserelin treatment support the use of this agent as an alternative to chemotherapy in this patient population. Patients should be provided with information on the benefits and risks associated with available treatment options so that they can be involved in the decision-making process.


Files in this item

This item appears in the following Collection(s)

Show simple item record